id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
15126179_3 | PURPOSE: To report a case of angiographically documented cystoid macula edema occurring after switching a pseudophakic patient from latanoprost to bimatoprost. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"switching\"]], \"start\": [[94]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a pseudophakic patient\"]], \"start\": [[104]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"from latanoprost to bimatoprost.\"]], \"start\": [[127]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"latanoprost\"], [\"bimatoprost\"]], \"start\": [[132], [147]], \"entity_id\": [\"T9\", \"T10\"]}, \"Disorder\": {\"text\": [[\"pseudophakic\"]], \"start\": [[106]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"case of angiographically documented cystoid macula edema\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
15013892_4 | The clinical picture was identical to that of chloroquine and hydroxychloroquine maculopathy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"identical\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"chloroquine and hydroxychloroquine\"]], \"start\": [[46]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"chloroquine\"], [\"hydroxychloroquine\"]], \"start\": [[46], [62]], \"entity_id\": [\"T7\", \"T8\"]}}, \"Effect\": {\"text\": [[\"maculopathy\"]], \"start\": [[81]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19299370_2 | CONCLUSION: A woman receiving enoxaparin every 12 hours developed signs and symptoms of hepatotoxicity after the second dose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[56]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A woman\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"enoxaparin every 12 hours\", \"after the second dose\"]], \"start\": [[30, 103]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"enoxaparin\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}, \"Freq\": {\"text\": [[\"every 12 hours\"]], \"start\": [[41]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"the second dose.\"]], \"start\": [[109]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"signs and symptoms of hepatotoxicity\"]], \"start\": [[66]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
1747495_2 | A case of liver damage following treatment with Danazol for fibrocystic breast disease is reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[23]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"liver damage\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Danazol\"]], \"start\": [[48]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Danazol\"]], \"start\": [[48]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"fibrocystic breast disease\"]], \"start\": [[60]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
2257522_1 | Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Antacid and sucralfate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"sucralfate\"], [\"Antacid\"]], \"start\": [[12], [0]], \"entity_id\": [\"T7\", \"T8\"]}}, \"Effect\": {\"text\": [[\"hypophosphatemic osteomalacia\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16268429_3 | We report a case of senna-induced cholestatic hepatitis which was not diagnosed at presentation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[26]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"senna\"]], \"start\": [[20]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"senna\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"cholestatic hepatitis\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
788666_1 | Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"responsible\"]], \"start\": [[69]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[85]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"Five patients\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"Five\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"gentamicin sulfate\"]], \"start\": [[41]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"gentamicin sulfate\"]], \"start\": [[41]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"appeared\"]], \"start\": [[60]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
12852380_1 | However, in order to avoid neuropathic side effects, patients under thalidomide therapy should be monitored every 6 months with nerve conduction studies while taking the drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"under\"]], \"start\": [[62]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"neuropathic side effects\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[53]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"thalidomide therapy\"]], \"start\": [[68]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"thalidomide\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
16200540_3 | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"demonstrated\"]], \"start\": [[92]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"levodopa\"]], \"start\": [[76]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"levodopa\"]], \"start\": [[76]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia\"]], \"start\": [[105]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
3873709_1 | Antibiotic-associated colitis (pseudomembranous colitis) developed in four patients with spinal cord injury and taking oral trimethoprim-sulfamethoxazole. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[57]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"four patients with spinal cord injury\"]], \"start\": [[70]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"four\"]], \"start\": [[70]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"oral trimethoprim-sulfamethoxazole\"]], \"start\": [[119]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"sulfamethoxazole\"], [\"trimethoprim\"]], \"start\": [[137], [124]], \"entity_id\": [\"T13\", \"T14\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[119]], \"entity_id\": [\"T16\"]}, \"Disorder\": {\"text\": [[\"spinal cord injury\"]], \"start\": [[89]], \"entity_id\": [\"T17\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"-\"]], \"start\": [[136]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"trimethoprim\"], [\"sulfamethoxazole\"]], \"start\": [[124], [137]], \"entity_id\": [\"T14\", \"T13\"]}}]}, \"Effect\": {\"text\": [[\"Antibiotic-associated colitis (pseudomembranous colitis)\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
16641839_5 | We report the case of a 27-year-old Indian woman who developed maculopapular rash and angioedema secondary to carbamazepine administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a 27-year-old Indian woman\"]], \"start\": [[22]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"27-year-old\"]], \"start\": [[24]], \"entity_id\": [\"T9\"]}, \"Race\": {\"text\": [[\"Indian\"]], \"start\": [[36]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[43]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"maculopapular rash and angioedema\"]], \"start\": [[63]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"carbamazepine administration\"]], \"start\": [[110]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[110]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"administration\"]], \"start\": [[124]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
16396068_3 | We reviewed the literature in an attempt to characterize the pattern and predictors of TMP/SMX-induced aseptic meningitis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[95]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"TMP/SMX\"]], \"start\": [[87]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"TMP\"], [\"SMX\"]], \"start\": [[87], [91]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"/\"]], \"start\": [[90]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"SMX\"], [\"TMP\"]], \"start\": [[91], [87]], \"entity_id\": [\"T8\", \"T7\"]}}]}, \"Effect\": {\"text\": [[\"aseptic meningitis\"]], \"start\": [[103]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12324937_4 | Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"onset\"]], \"start\": [[56]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine\"]], \"start\": [[73]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[119]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"7.4 +/- 3.5 months\"]], \"start\": [[73]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"21.9 +/- 10.9 doses\"]], \"start\": [[96]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"HUS\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8684546_1 | Aluminum intoxication, along with other factors, was considered to be the cause of TC development. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[74]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Aluminum intoxication\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Aluminum\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"TC development\"]], \"start\": [[83]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"considered\"]], \"start\": [[53]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
11999915_1 | Agranulocytosis during clozapine therapy. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[16]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"clozapine therapy\"]], \"start\": [[23]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Agranulocytosis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
14746605_1 | It was highly suspected that finasteride was associated with the anterior subcapsular opacity on the lens, and the patient therefore discontinued use of finasteride. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"finasteride\"]], \"start\": [[29]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"finasteride\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"anterior subcapsular opacity on the lens\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[111]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"highly suspected\"]], \"start\": [[7]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
2811895_2 | Life-threatening cranial dystonia following trihexyphenidyl withdrawal. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"cranial dystonia\"]], \"start\": [[17]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"trihexyphenidyl withdrawal\"]], \"start\": [[44]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"trihexyphenidyl\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}}, \"Severity\": {\"text\": [[\"Life-threatening\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
3982906_3 | The risk of cardiac decompensation in infants with supraventricular tachycardia and congestive cardiac failure should be kept in mind prior to administration of verapamil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"cardiac decompensation\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"verapamil\"]], \"start\": [[161]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"verapamil\"]], \"start\": [[161]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"supraventricular tachycardia\"]], \"start\": [[51]], \"entity_id\": [\"T1\"]}}, \"Subject\": {\"text\": [[\"infants with supraventricular tachycardia and congestive cardiac failure\"]], \"start\": [[38]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"congestive cardiac failure\"]], \"start\": [[84]], \"entity_id\": [\"T4\"]}, \"Age\": {\"text\": [[\"infants\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
18171260_5 | We describe serotonin syndrome after concomitant use of linezolid and meperidine in a 27-year-old man with acute leukemia. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[31]], \"entity_id\": [\"T13\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"concomitant use of linezolid and meperidine\"]], \"start\": [[37]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"linezolid\"], [\"meperidine\"]], \"start\": [[56], [70]], \"entity_id\": [\"T16\", \"T17\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[66]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"linezolid\"], [\"meperidine\"]], \"start\": [[56], [70]], \"entity_id\": [\"T16\", \"T17\"]}}]}, \"Subject\": {\"text\": [[\"a 27-year-old man with acute leukemia\"]], \"start\": [[84]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"acute leukemia\"]], \"start\": [[107]], \"entity_id\": [\"T12\"]}, \"Age\": {\"text\": [[\"27-year-old\"]], \"start\": [[86]], \"entity_id\": [\"T14\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[98]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
9191742_1 | Recent studies have shown that under experimental conditions ferrous sulfate may reduce the gastrointestinal absorption of orally administered levothyroxine sodium in patients with primary hypothyroidism. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reduce\"]], \"start\": [[81]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"reduce the gastrointestinal absorption of orally administered levothyroxine sodium\"]], \"start\": [[81]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ferrous sulfate\", \"orally administered levothyroxine sodium\"]], \"start\": [[61, 123]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ferrous sulfate\"], [\"levothyroxine sodium\"]], \"start\": [[61], [143]], \"entity_id\": [\"T9\", \"T12\"]}, \"Route\": {\"text\": [[\"orally\"]], \"start\": [[123]], \"entity_id\": [\"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"administered\"]], \"start\": [[130]], \"entity_id\": [\"T1\"]}, \"Drug\": {\"text\": [[\"ferrous sulfate\"], [\"levothyroxine sodium\"]], \"start\": [[61], [143]], \"entity_id\": [\"T9\", \"T12\"]}}]}, \"Subject\": {\"text\": [[\"patients with primary hypothyroidism\"]], \"start\": [[167]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"primary hypothyroidism\"]], \"start\": [[181]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[77]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
19775485_2 | We report here a case of cardiovascular and neurological depression induced by oxymetalzoline in a toddler. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[68]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"oxymetalzoline\"]], \"start\": [[79]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"oxymetalzoline\"]], \"start\": [[79]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"cardiovascular and neurological depression\"]], \"start\": [[25]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a toddler\"]], \"start\": [[97]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"toddler\"]], \"start\": [[99]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10431414_3 | The association between heparin and priapism is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[24]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"priapism\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12078977_2 | Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Posterior leukoencephalopathy\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary\"]], \"start\": [[40]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"germ cell tumor of the ovary\"]], \"start\": [[89]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"cisplatin\"], [\"bleomycin\"], [\"vinblastine\"]], \"start\": [[40], [51], [65]], \"entity_id\": [\"T9\", \"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[61]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"vinblastine\"], [\"bleomycin\"], [\"cisplatin\"]], \"start\": [[65], [51], [40]], \"entity_id\": [\"T11\", \"T10\", \"T9\"]}}]}}"
}
]
}
] |
12086549_2 | OBJECTIVE: To report a case of cutaneous and hematologic toxicity in a patient treated with IL-2. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"case\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[69]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"IL-2\"]], \"start\": [[92]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"IL-2\"]], \"start\": [[92]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"cutaneous and hematologic toxicity\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10707759_2 | Flecainide is a rare cause of hypersensitivity pneumonitis, and few cases have been reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Flecainide\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Flecainide\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity pneumonitis\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17536204_5 | The patient developed grade 3 capecitabine-induced headache. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[43]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"capecitabine\"]], \"start\": [[30]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"capecitabine\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"headache\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
1951476_2 | We report a case of biopsy-proven acute tubulointerstitial nephritis associated with a second course of flurbiprofen, a nonsteroidal anti-inflammatory drug of the propionic acid class. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[69]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"a second course of flurbiprofen\"]], \"start\": [[85]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"flurbiprofen\"]], \"start\": [[104]], \"entity_id\": [\"T6\"]}, \"Freq\": {\"text\": [[\"second course\"]], \"start\": [[87]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"biopsy-proven acute tubulointerstitial nephritis\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
1378497_1 | Although an association between exposure to bleomycin and the development of scleroderma has been suspected, few cases are reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"bleomycin\"]], \"start\": [[44]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"bleomycin\"]], \"start\": [[44]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"scleroderma\"]], \"start\": [[77]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"few cases\"]], \"start\": [[109]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"suspected\"]], \"start\": [[98]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
10987357_2 | A 74-year-old man received oral administration of pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[185]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 74-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Age\": {\"text\": [[\"74-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"oral administration of pilsicainide\", \"two days later\"]], \"start\": [[27, 217]], \"entity_id\": [\"T9\"], \"Route\": {\"text\": [[\"oral\"]], \"start\": [[27]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"pilsicainide\"]], \"start\": [[50]], \"entity_id\": [\"T15\"]}, \"Disorder\": {\"text\": [[\"paroxysmal atrial fibrillation\"]], \"start\": [[134]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"two days later\"]], \"start\": [[217]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"loss of consciousness\"]], \"start\": [[195]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
11876387_1 | Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Aggressive endometrial carcinoma\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"tamoxifen\"]], \"start\": [[73]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[73]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"breast cancer patient\", \"with normal transvaginal ultrasonography\"]], \"start\": [[38, 83]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
8792511_1 | Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"include\"]], \"start\": [[38]], \"entity_id\": [\"T27\"]}, \"Treatment\": {\"text\": [[\"dapsone\"]], \"start\": [[30]], \"entity_id\": [\"T25\"], \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[30]], \"entity_id\": [\"T28\"]}}, \"Effect\": {\"text\": [[\"the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints\"]], \"start\": [[46]], \"entity_id\": [\"T26\"]}}"
}
]
}
] |
10475726_2 | The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[4]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"ischaemic events\"]], \"start\": [[46]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"venlafaxine treatment\"]], \"start\": [[19]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"venlafaxine\"]], \"start\": [[19]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
17060191_5 | This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to ductal closure in response to indomethacin exposure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"response\"]], \"start\": [[158]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"ductal closure\"]], \"start\": [[140]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"indomethacin exposure\"]], \"start\": [[170]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"indomethacin\"]], \"start\": [[170]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"exposure\"]], \"start\": [[183]], \"entity_id\": [\"T13\"]}}, \"Speculated\": {\"text\": [[\"susceptible\"]], \"start\": [[125]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
8903300_3 | This pattern is suggestive of renal toxicity due to tobramycin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[45]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"renal toxicity\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"tobramycin\"]], \"start\": [[52]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"tobramycin\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"suggestive\"]], \"start\": [[16]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
8742573_4 | OBJECTIVE: To evaluate the efficacy of the administration of insulin by a jet-injector device in stopping and reversing severe human insulin-induced lipoatrophy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[141]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"severe human\", \"lipoatrophy\"]], \"start\": [[120, 149]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"insulin\"]], \"start\": [[133]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"insulin\"]], \"start\": [[133]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2442958_2 | This is a unique autopsy case of hepatocellular carcinoma closely related to diethylstilbestrol (DES) therapy for prostatic cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[66]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a unique autopsy case\"]], \"start\": [[8]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"diethylstilbestrol (DES)\"]], \"start\": [[77]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"prostatic cancer\"]], \"start\": [[114]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"diethylstilbestrol\"]], \"start\": [[77]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hepatocellular carcinoma\"]], \"start\": [[33]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
12921505_2 | Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"for\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Argatroban\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"hepato-renal failur\"]], \"start\": [[51]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"Argatroban\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
1592841_1 | Falling backward in two elderly patients taking bupropion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"taking\"]], \"start\": [[41]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"two elderly patients\"]], \"start\": [[20]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"bupropion\"]], \"start\": [[48]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"bupropion\"]], \"start\": [[48]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Falling backward\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
11881322_4 | METHODS: Three patients with apparent itraconazole-induced liver injury were studied. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[51]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"itraconazole\"]], \"start\": [[38]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"itraconazole\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"liver injury\"]], \"start\": [[59]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"Three patients\"]], \"start\": [[9]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"Three\"]], \"start\": [[9]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
15907341_2 | Six patients developed peripheral neuropathy and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of linezolid. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"normalized\"]], \"start\": [[181]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"all five patients\"]], \"start\": [[142]], \"entity_id\": [\"T21\"], \"Population\": {\"text\": [[\"five\"]], \"start\": [[146]], \"entity_id\": [\"T25\"]}}, \"Treatment\": {\"text\": [[\"cessation of linezolid\"]], \"start\": [[198]], \"entity_id\": [\"T22\"], \"Disorder\": {\"text\": [[\"bone marrow depression\"]], \"start\": [[63]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[211]], \"entity_id\": [\"T23\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[13]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"linezolid\"]], \"start\": [[211]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[211]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"Six patients\"]], \"start\": [[0]], \"entity_id\": [\"T14\"], \"Population\": {\"text\": [[\"Six\"]], \"start\": [[0]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"peripheral neuropathy\"]], \"start\": [[23]], \"entity_id\": [\"T16\"]}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[13]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"linezolid\"]], \"start\": [[211]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[211]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"five patients\"]], \"start\": [[49]], \"entity_id\": [\"T17\"], \"Population\": {\"text\": [[\"five\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"bone marrow depression\"]], \"start\": [[63]], \"entity_id\": [\"T10\"]}}"
},
{
"event_id": "E4",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E4\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"given\"]], \"start\": [[111]], \"entity_id\": [\"T20\"]}, \"Treatment\": {\"text\": [[\"blood transfusions\", \"cessation of linezolid\"]], \"start\": [[87, 198]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"linezolid\"]], \"start\": [[211]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"three patients\"]], \"start\": [[120]], \"entity_id\": [\"T19\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[120]], \"entity_id\": [\"T24\"]}}}"
}
]
}
] |
12111771_5 | To our knowledge, four cases of interstitial pneumonitis associated with fludarabine have been reported in medical literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"interstitial pneumonitis\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"fludarabine\"]], \"start\": [[73]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"fludarabine\"]], \"start\": [[73]], \"entity_id\": [\"T3\"]}}}"
}
]
}
] |
20397038_1 | Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[77]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Normalization of generalized retinal function and progression of maculopathy\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cessation of therapy\", \"hydroxychloroquine\"]], \"start\": [[83, 124]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"hydroxychloroquine\"]], \"start\": [[124]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"hydroxychloroquine retinopathy\"]], \"start\": [[124]], \"entity_id\": [\"T9\"]}, \"Time_elapsed\": {\"text\": [[\"19 years\"]], \"start\": [[160]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"a case of severe hydroxychloroquine retinopathy\"]], \"start\": [[107]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[117]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
20118434_2 | Interferon-induced psychosis as a "psychiatric contraindication" to hepatitis C treatment: a review and case-based discussion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"psychosis\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Interferon\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Interferon\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"hepatitis C\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10524732_1 | Prolongation of the QT interval and ventricular tachyarrhymias have been described in patients on amiodarone therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"described\"]], \"start\": [[73]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Prolongation of the QT interval and ventricular tachyarrhymias\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[86]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"amiodarone therapy\"]], \"start\": [[98]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[98]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
17420198_9 | Aripiprazole, 5 mg daily, was initiated in November 2004 as an augmentation strategy for the diagnosis of OCD. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"augmentation\"]], \"start\": [[63]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Aripiprazole\", \"5 mg daily\"]], \"start\": [[0, 14]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"OCD\"]], \"start\": [[106]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"Aripiprazole\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Dosage\": {\"text\": [[\"5 mg\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Freq\": {\"text\": [[\"daily\"]], \"start\": [[19]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
11250985_4 | Serious adverse events experienced by patients with chronic heart failure taking spironolactone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Serious adverse events\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"spironolactone\"]], \"start\": [[81]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"spironolactone\"]], \"start\": [[81]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"patients with chronic heart failure\"]], \"start\": [[38]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"chronic heart failure\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
941054_2 | Review of the literature relating to methicillin-induced nephropathy suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[49]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methicillin\"]], \"start\": [[37]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"methicillin\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"nephropathy\", \"hypersensitivity\"]], \"start\": [[57, 80]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"suggests\"]], \"start\": [[69]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
16298824_2 | ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[14]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"ARDS\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3\"]], \"start\": [[30]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"infliximab\"], [\"gemtuzumab\"], [\"ozogamicin\"], [\"OKT3\"]], \"start\": [[89], [101], [112], [128]], \"entity_id\": [\"T8\", \"T9\", \"T10\", \"T11\"]}}}"
}
]
}
] |
12365708_3 | CASE REPORT: Soon after initiation of amiodarone HCl (200 mg/day), a 76-year-old man came to us with symptoms of visual "shining," glare, color vision anomalies, and gradually decreased vision. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after initiation\"]], \"start\": [[18]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"a 76-year-old man\"]], \"start\": [[67]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"76-year-old\"]], \"start\": [[69]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[81]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"symptoms of visual \\\"shining,\\\" glare, color vision anomalies, and gradually decreased vision\"]], \"start\": [[101]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"amiodarone HCl\"]], \"start\": [[38]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"amiodarone HCl\"]], \"start\": [[38]], \"entity_id\": [\"T15\"]}, \"Dosage\": {\"text\": [[\"(200 mg\"]], \"start\": [[53]], \"entity_id\": [\"T16\"]}, \"Freq\": {\"text\": [[\"day\"]], \"start\": [[61]], \"entity_id\": [\"T17\"]}}}"
}
]
}
] |
527355_1 | An insulin-dependent diabetic patient with nephropathy developed severe acidosis after treatment with acetazolamide for glaucoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"severe acidosis\"]], \"start\": [[65]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"An insulin-dependent diabetic patient with nephropathy\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"diabetic\"], [\"nephropathy\"]], \"start\": [[21], [43]], \"entity_id\": [\"T8\", \"T9\"]}}, \"Treatment\": {\"text\": [[\"acetazolamide for glaucoma\"]], \"start\": [[102]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"glaucoma\"]], \"start\": [[120]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"acetazolamide\"]], \"start\": [[102]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[65]], \"entity_id\": [\"T10\"], \"value\": \"Medium\"}}"
}
]
}
] |
15504988_1 | Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"hypo-alpha-lipoproteinemia\"]], \"start\": [[7]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"rosiglitazone\"]], \"start\": [[56]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"rosiglitazone\"]], \"start\": [[56]], \"entity_id\": [\"T6\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
2445709_2 | Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Peripheral neuropathy and cerebellar syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[62]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
18691992_4 | CONCLUSIONS: We report this case of the concomitant appearance of multiple skin cancers and nail changes associated with hydroxyurea use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[105]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"multiple skin cancers and nail changes\"]], \"start\": [[66]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"hydroxyurea\"]], \"start\": [[121]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"hydroxyurea\"]], \"start\": [[121]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"case\"]], \"start\": [[28]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
9847899_1 | As this relapse coincided with development of a strong delayed-type hypersensitivity response to tuberculin and improved after treatment with the anti-inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen-specific cellular immunity. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"a strong delayed-type hypersensitivity response\"]], \"start\": [[46]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"tuberculin\"]], \"start\": [[97]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"tuberculin\"]], \"start\": [[97]], \"entity_id\": [\"T7\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"improved\"]], \"start\": [[112]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"anti-inflammatory agent oxpentifylline\"]], \"start\": [[146]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"this relapse\"]], \"start\": [[3]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"oxpentifylline\"]], \"start\": [[170]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
16012330_1 | Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Itraconazole\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Itraconazole\"], [\"vincristine\"]], \"start\": [[0], [31]], \"entity_id\": [\"T8\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"increased\"]], \"start\": [[21]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"Itraconazole\"], [\"vincristine\"]], \"start\": [[0], [31]], \"entity_id\": [\"T8\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"increased vincristine neurotoxicity\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11837564_1 | A 62-year-old Caucasian man with atrial fibrillation who was taking warfarin reported an episode of hematochezia; his international normalized ratio (INR) was 1.74. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"episode\"]], \"start\": [[89]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 62-year-old Caucasian man with atrial fibrillation\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"62-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Race\": {\"text\": [[\"Caucasian\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[24]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"warfarin\"]], \"start\": [[68]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"atrial fibrillation\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[68]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"hematochezia\"]], \"start\": [[100]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
22233409_1 | Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction? | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"anaemia\"]], \"start\": [[7]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"oseltamivir during treatment of chronic hepatitis C\"]], \"start\": [[26]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"oseltamivir\"]], \"start\": [[26]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[58]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"value\": \"Medium\"}}"
}
]
}
] |
10084639_1 | BACKGROUND: How to best treat psychotic patients who have had past clozapine-induced agranulocytosis or granulocytopenia remains a problem. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[77]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"psychotic patients\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[67]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"psychotic\"]], \"start\": [[30]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"agranulocytosis or granulocytopenia\"]], \"start\": [[85]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
15126179_1 | Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[22]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Cystoid macular edema\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"low-risk patient\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"switching from latanoprost to bimatoprost\"]], \"start\": [[50]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"bimatoprost\"], [\"latanoprost\"]], \"start\": [[80], [65]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"switching\"]], \"start\": [[50]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"latanoprost\"], [\"bimatoprost\"]], \"start\": [[65], [80]], \"entity_id\": [\"T9\", \"T8\"]}}]}}"
}
]
}
] |
7439122_3 | Physicians should therefore be aware of its occurrence and carefully monitor serum levels of CPK, GOT and GPT during the treatment of diabetes insipidus with clofibrate, especially in patients with associated hypothyroidism, latent or overt, which possibly favors the development of myopathy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[268]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"patients with associated hypothyroidism, latent or overt\"]], \"start\": [[184]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"hypothyroidism\"], [\"latent\"], [\"overt\"]], \"start\": [[209], [225], [235]], \"entity_id\": [\"T8\", \"T1\", \"T2\"]}}, \"Treatment\": {\"text\": [[\"clofibrate\"]], \"start\": [[158]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"diabetes insipidus\"]], \"start\": [[134]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"clofibrate\"]], \"start\": [[158]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"myopathy.\"]], \"start\": [[283]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"possibly\"]], \"start\": [[248]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
1951476_1 | Flurbiprofen-associated acute tubulointerstitial nephritis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[13]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Flurbiprofen\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Flurbiprofen\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"acute tubulointerstitial nephritis\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9302445_1 | CONCLUSION: We believe this to be the first reported case of rhGH-induced hypercalcemia in an HIV-infected patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[66]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"rhGH\"]], \"start\": [[61]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"rhGH\"]], \"start\": [[61]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"HIV\"]], \"start\": [[94]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hypercalcemia\"]], \"start\": [[74]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an HIV-infected patient\"]], \"start\": [[91]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7946029_2 | A case of basilar invagination which is thought to have arisen from the patient's intrauterine exposure to phenytoin is presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exposure\"]], \"start\": [[95]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"basilar invagination\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"phenytoin\"]], \"start\": [[107]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[107]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"intrauterine\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
1495728_1 | Methotrexate pneumonitis in nonsurgical treatment of ectopic pregnancy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"nonsurgical treatment\"]], \"start\": [[28]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"ectopic pregnancy\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Methotrexate pneumonitis\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
3767790_2 | Two patients who were receiving Tolazoline by infusion developed duodenal ulceration and subsequent intestinal perforation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"Two patients\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"receiving Tolazoline by infusion\"]], \"start\": [[22]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Tolazoline\"]], \"start\": [[32]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[46]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"duodenal ulceration and subsequent intestinal perforation\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
20098333_2 | We report the case of a 14-year-old female with acute promyelocytic leukemia who developed symptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA). | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[81]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 14-year-old female with acute promyelocytic leukemia\"]], \"start\": [[22]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"14-year-old\"]], \"start\": [[24]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[36]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"symptomatic cardiomyopathy\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"4 months into treatment with a combination of daunomycin and all-trans retinoic acid (ATRA)\"]], \"start\": [[123]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"acute promyelocytic leukemia\"]], \"start\": [[48]], \"entity_id\": [\"T12\"]}, \"Time_elapsed\": {\"text\": [[\"4 months\"]], \"start\": [[123]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"daunomycin\"], [\"all-trans retinoic acid\"]], \"start\": [[169], [184]], \"entity_id\": [\"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[154]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"daunomycin\"], [\"all-trans retinoic acid\"]], \"start\": [[169], [184]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Severity\": {\"text\": [[\"acute\"]], \"start\": [[48]], \"entity_id\": [\"T17\"], \"value\": \"High\"}}"
}
]
}
] |
17228132_3 | Hepatotoxicity seen with erlotinib, a small molecule tyrosine kinase inhibitor to EGFR, is usually transient with mild elevation of transaminases. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"seen\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[25]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Hepatotoxicity\", \"transient with mild elevation of transaminases\"]], \"start\": [[0, 99]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
18585545_5 | RESULTS: A previously healthy 42-year-old woman presented with acute-onset delirium with psychotic features as a consequence of levofloxacin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"as a consequence of\"]], \"start\": [[108]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A previously healthy 42-year-old woman\"]], \"start\": [[9]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"42-year-old\"]], \"start\": [[30]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[42]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"acute-onset delirium with psychotic features\"]], \"start\": [[63]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"levofloxacin therapy\"]], \"start\": [[128]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"levofloxacin\"]], \"start\": [[128]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
22791547_5 | Although limb dyskinesia after methylphenidate is a commonly reported side effect, to the authors' knowledge this is only the second reported case to develop both orofacial and limb dyskinesia in the acute period after the first dose of methylphenidate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[150]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"the second reported case\"]], \"start\": [[122]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"orofacial and limb dyskinesia\"]], \"start\": [[163]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"methylphenidate\"]], \"start\": [[237]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"methylphenidate\"], [\"methylphenidate\"]], \"start\": [[31], [237]], \"entity_id\": [\"T11\", \"T12\"]}}, \"Speculated\": {\"text\": [[\"only the second reported case\"]], \"start\": [[117]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
7995508_1 | Phenylpropanolamine-induced psychosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Phenylpropanolamine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Phenylpropanolamine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"psychosis\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
3763264_1 | Graft versus host-like illness in a child with phenobarbital hypersensitivity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"hypersensitivity\"]], \"start\": [[61]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"a child\"]], \"start\": [[34]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[36]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"Graft versus host-like illness\", \"hypersensitivity\"]], \"start\": [[0, 61]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"phenobarbital\"]], \"start\": [[47]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"phenobarbital\"]], \"start\": [[47]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8597009_4 | The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"suspect\"]], \"start\": [[89]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"phenytoin\"]], \"start\": [[16]], \"entity_id\": [\"T4\"], \"Duration\": {\"text\": [[\"tuberculosis\"]], \"start\": [[44]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[16]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"phenytoin toxicity\"]], \"start\": [[185]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[122]], \"entity_id\": [\"T8\"]}, \"Speculated\": {\"text\": [[\"suspect\"]], \"start\": [[89]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
9660541_3 | We report a case of MMC-related hemolytic uremic syndrome, and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"MMC\"]], \"start\": [[20]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"MMC\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hemolytic uremic syndrome\"]], \"start\": [[32]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[158]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
3947272_3 | Myasthenic patients receiving ampicillin should be closely monitored for possible acute exacerbations. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ampicillin\"]], \"start\": [[30]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"Myasthenic\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"ampicillin\"]], \"start\": [[30]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"Myasthenic patients\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute exacerbations\"]], \"start\": [[82]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[73]], \"entity_id\": [\"T3\"], \"value\": true}}"
}
]
}
] |
11999915_4 | The male patient was treated with 225-mg/day clozapine and the time to the diagnosis of agranulocytosis was 6 weeks. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"diagnosis\"]], \"start\": [[75]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"The male patient\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"male\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"225-mg/day clozapine\"]], \"start\": [[34]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[45]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"225-mg/day\"]], \"start\": [[34]], \"entity_id\": [\"T9\"]}, \"Duration\": {\"text\": [[\"6 weeks\"]], \"start\": [[108]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"agranulocytosis\"]], \"start\": [[88]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2862137_2 | Alprazolam withdrawal delirium unresponsive to diazepam: case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[44]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"diazepam\"]], \"start\": [[47]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"Alprazolam withdrawal delirium\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"diazepam\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}}, \"Negated\": {\"text\": [[\"unresponsive\"]], \"start\": [[31]], \"entity_id\": [\"T4\"], \"value\": true}}"
}
]
}
] |
4036917_3 | These findings support previous studies that showed that the use of aspirin during the antecedent illness may be a risk factor for the development of RS. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[135]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"aspirin\"]], \"start\": [[68]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"the antecedent illness\"]], \"start\": [[83]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"aspirin\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"RS\"]], \"start\": [[150]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[106]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
16405935_1 | Chloroquine-induced bilateral ptosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Chloroquine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Chloroquine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"bilateral ptosis\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17364199_14 | DISCUSSION: To our knowledge this is the first reported case of tuberculous uveitis following treatment with etanercept. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[104]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"tuberculous uveitis\"]], \"start\": [[64]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"etanercept\"]], \"start\": [[109]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"etanercept\"]], \"start\": [[109]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
25538343_2 | Hyponatremia is a known adverse effect of duloxetine, and it can lead to potentially life-threatening complications. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"duloxetine\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"duloxetine\"]], \"start\": [[42]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Hyponatremia\"], [\"potentially life-threatening complications\"]], \"start\": [[0], [73]], \"entity_id\": [\"T6\", \"T7\"]}, \"Severity\": {\"text\": [[\"life-threatening\"]], \"start\": [[85]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
19003750_1 | A 22-year-old drug-abuser injected flunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of acute ischaemia of the left leg. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[113]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 22-year-old drug-abuser\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"22-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"drug-abuser\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"injected flunitrazepam tablets dissolved in tap water into her left femoral artery\"]], \"start\": [[26]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"flunitrazepam\"]], \"start\": [[35]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"injected\", \"tablets dissolved in tap water\"]], \"start\": [[26, 49]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"acute ischaemia of the left leg\"]], \"start\": [[146]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
1348483_1 | A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[108]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A patient with Parkinson's disease\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"initially treated with bromocriptine and subsequently with cabergoline\"]], \"start\": [[36]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"Parkinson's disease\"]], \"start\": [[15]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"bromocriptine\"], [\"cabergoline\"]], \"start\": [[59], [95]], \"entity_id\": [\"T9\", \"T10\"]}}, \"Effect\": {\"text\": [[\"progressive pleuropulmonary abnormalities during the latter therapy\"]], \"start\": [[118]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16432996_3 | Although interferon gamma has been implicated in the pathogenesis of sarcoidosis, only a few cases of sarcoidosis associated with interferon alpha therapy have been reported. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"pathogenesis\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"interferon gamma\"]], \"start\": [[9]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"interferon gamma\"]], \"start\": [[9]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"sarcoidosis\"]], \"start\": [[69]], \"entity_id\": [\"T9\"]}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[114]], \"entity_id\": [\"T14\"]}, \"Effect\": {\"text\": [[\"sarcoidosis\"]], \"start\": [[102]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"interferon alpha\"]], \"start\": [[130]], \"entity_id\": [\"T15\"], \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[130]], \"entity_id\": [\"T16\"]}}, \"Speculated\": {\"text\": [[\"only a few cases\"]], \"start\": [[82]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
3143551_3 | Camptocormia, a new side effect of sodium valproate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Camptocormia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"sodium valproate\"]], \"start\": [[35]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sodium valproate\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
15028964_2 | Many patients with cardiac arrhythmias require concomitant therapy with warfarin and amiodarone. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"require\"]], \"start\": [[39]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"Many patients with cardiac arrhythmias\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"concomitant therapy with warfarin and amiodarone\"]], \"start\": [[47]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"warfarin\"], [\"amiodarone\"]], \"start\": [[72], [85]], \"entity_id\": [\"T11\", \"T12\"]}, \"Disorder\": {\"text\": [[\"cardiac arrhythmias\"]], \"start\": [[19]], \"entity_id\": [\"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitant\"]], \"start\": [[47]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"warfarin\"], [\"amiodarone\"]], \"start\": [[72], [85]], \"entity_id\": [\"T11\", \"T12\"]}}]}}"
}
]
}
] |
11373877_2 | We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed femoral head avascular necrosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[129]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"two patients with histologically confirmed adenocarcinoma of the prostate\"]], \"start\": [[32]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[32]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"steroidal anti-androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation\"]], \"start\": [[142]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"adenocarcinoma of the prostate\"]], \"start\": [[75]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"cyproterone acetate\"]], \"start\": [[189]], \"entity_id\": [\"T1\"]}}, \"Effect\": {\"text\": [[\"femoral head avascular necrosis.\"]], \"start\": [[291]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16284443_3 | Thus, the possible in vivo effects of insulin on adipocytes were clearly observed in this case of insulin-induced lipohypertrophy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[106]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"insulin\"]], \"start\": [[98]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"insulin\"]], \"start\": [[98]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"lipohypertrophy\"]], \"start\": [[114]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[10]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
10599932_5 | After the addition of citalopram, a desmethylclomipramine plasma level increase and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"desmethylclomipramine plasma level increase and an 8-hydroacy-desmethylclomipramine plasma level decrease\"]], \"start\": [[36]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"citalopram\"]], \"start\": [[22]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"citalopram\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16791713_3 | Here we present the case of a woman who received high doses of methylprednisolone (1 g iv daily) for active Graves' ophthalmopathy, and developed severe hypertension followed by myocardial infarction on the fifth day of treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"received\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a woman\"]], \"start\": [[28]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[30]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"high doses of methylprednisolone (1 g iv daily)\"]], \"start\": [[49]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"methylprednisolone\"]], \"start\": [[63]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"1 g\"]], \"start\": [[83]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"iv\"]], \"start\": [[87]], \"entity_id\": [\"T12\"]}, \"Freq\": {\"text\": [[\"daily\"]], \"start\": [[90]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"active Graves' ophthalmopathy\"]], \"start\": [[101]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"severe hypertension followed by myocardial infarction on the fifth day of treatment.\"]], \"start\": [[146]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[146]], \"entity_id\": [\"T15\"], \"value\": \"High\"}}"
}
]
}
] |
19875411_2 | Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"cardiomyopathy\"]], \"start\": [[7]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"treatment with the tumour necrosis factor-alpha inhibitor adalimumab\"]], \"start\": [[32]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"adalimumab\"]], \"start\": [[90]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[105]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
7991279_2 | There are now reports of liver failure following treatment of childhood cancers with AMD. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"childhood cancers\"]], \"start\": [[62]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"childhood\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"liver failure\"]], \"start\": [[25]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"AMD\"]], \"start\": [[85]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"cancers\"]], \"start\": [[72]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"AMD\"]], \"start\": [[85]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
18362995_2 | Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[18]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"fatal acute hepatic failure\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Imatinib mesylate\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Imatinib mesylate\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"chronic myeloid leukaemia\"]], \"start\": [[72]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"a patient with chronic myeloid leukaemia and chronic hepatitis B infection\"]], \"start\": [[57]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"chronic hepatitis B infection\"]], \"start\": [[102]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[26]], \"entity_id\": [\"T8\"], \"value\": \"High\"}}"
}
]
}
] |
11889149_3 | This phase 3, randomized, double-blind 1-yr study assessed the effects of combined RLX and ALN in 331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2). | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"effects\"]], \"start\": [[63]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"combined RLX and ALN\"]], \"start\": [[74]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"osteoporosis\"]], \"start\": [[128]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"RLX\"], [\"ALN\"]], \"start\": [[83], [91]], \"entity_id\": [\"T18\", \"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combined\"]], \"start\": [[74]], \"entity_id\": [\"T20\"]}, \"Drug\": {\"text\": [[\"RLX\"], [\"ALN\"]], \"start\": [[83], [91]], \"entity_id\": [\"T18\", \"T19\"]}}]}, \"Subject\": {\"text\": [[\"331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2)\"]], \"start\": [[98]], \"entity_id\": [\"T9\"], \"Population\": {\"text\": [[\"331\"]], \"start\": [[98]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"women\"]], \"start\": [[117]], \"entity_id\": [\"T13\"]}, \"Age\": {\"text\": [[\"postmenopausal\"]], \"start\": [[102]], \"entity_id\": [\"T16\"]}}, \"Speculated\": {\"text\": [[\"assessed\"]], \"start\": [[50]], \"entity_id\": [\"T17\"], \"value\": true}}"
}
]
}
] |
8597009_1 | Phenytoin toxicity due to concomitant antituberculosis therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Phenytoin toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"concomitant antituberculosis therapy.\"]], \"start\": [[26]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Phenytoin\"], [\"antituberculosis\"]], \"start\": [[0], [38]], \"entity_id\": [\"T6\", \"T7\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitant\"]], \"start\": [[26]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"antituberculosis\"], [\"Phenytoin\"]], \"start\": [[38], [0]], \"entity_id\": [\"T7\", \"T6\"]}}]}}"
}
]
}
] |
7900744_2 | Hemodialysis should be performed for rapid reversal of mannitol-induced ARF. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[64]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"mannitol\"]], \"start\": [[55]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"mannitol\"]], \"start\": [[55]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"ARF\"]], \"start\": [[72]], \"entity_id\": [\"T5\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"performed\"]], \"start\": [[23]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"Hemodialysis\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"Hemodialysis\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"mannitol-induced ARF\"]], \"start\": [[55]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
18067642_2 | Amiodarone is well recognized as an anti-arrhythmic drug containing a high dose of iodine with considerable potential to cause thyroid dysfunction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"recognized\"]], \"start\": [[19]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Amiodarone\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Amiodarone\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"potential to cause thyroid dysfunction\"]], \"start\": [[108]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
1359782_2 | Pulmonary infiltrates and skin pigmentation associated with sulfasalazine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[44]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"sulfasalazine\"]], \"start\": [[60]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"sulfasalazine\"]], \"start\": [[60]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Pulmonary infiltrates and skin pigmentation\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
998323_1 | Lithium treatment was terminated in 1975 because of lithium intoxication with a diabetes insipidus-like syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"because\"]], \"start\": [[41]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Lithium treatment\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Lithium\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"lithium intoxication with a diabetes insipidus-like syndrome\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
7304798_2 | The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which L-dopa shortened the manic-depressive cycle length when administered in a double-blind trial. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"shortened\"]], \"start\": [[117]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a woman with a history of bipolar affective disorder\"]], \"start\": [[48]], \"entity_id\": [\"T7\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[50]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"bipolar affective disorder\"]], \"start\": [[74]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"L-dopa\"]], \"start\": [[110]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"L-dopa\"]], \"start\": [[110]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"shortened the manic-depressive cycle length\"]], \"start\": [[117]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
19402273_1 | Isoniazid causing breast tissue enlargement has been very rarely reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causing\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"breast tissue enlargement\"]], \"start\": [[18]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Isoniazid\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Isoniazid\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.